Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Contineum Therapeutics, Inc.
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
March 12, 2025
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
March 06, 2025
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
March 04, 2025
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
March 03, 2025
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
January 08, 2025
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
December 16, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
November 25, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
November 18, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics to Attend Upcoming Investor Conferences
November 13, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 06, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
August 28, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis
July 31, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
June 24, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
June 04, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
June 03, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
May 20, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 16, 2024
From
Contineum Therapeutics, Inc.
Via
Business Wire
Tickers
CTNM
Contineum Therapeutics Announces Pricing of Initial Public Offering
April 04, 2024
From
Contineum Therapeutics, Inc.
Via
GlobeNewswire
Pipeline Therapeutics Changes Name to Contineum Therapeutics to Reflect Expanded Focus on NI&I Therapeutic Indications (Neuroscience, Inflammation and Immunology)
December 13, 2023
From
Contineum Therapeutics, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.